IN
INDV.US Indivior PLC Ordinary Shares
- Market cap
- USD 4.28B
- P/E
- 10.2x
- P/B
- 145.25x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INDV.US undervalued?
Graham numberThe Graham number of Indivior PLC Ordinary Shares cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Indivior PLC Ordinary Shares fundamental analysis
No fundamental analysis for Indivior PLC Ordinary Shares yet.
Indivior PLC Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Indivior PLC Ordinary Shares
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorp…
Full company profileIndivior PLC Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Indivior PLC Ordinary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 969M | 1.15B | 960M | 785M | 647M | 791M | 901M | 1.09B | 1.19B | 1.24B | 1.35B |
| Gross Profit | 858M | 1.03B | 825M | 645M | 550M | 664M | 750M | 919M | 957M | 993M | 1.17B |
| Operating Income | 338M | 423M | 317M | 178M | -156M | 213M | -81.0M | -156M | 32.0M | 265M | 637M |
| EBITDA | 150M | 206M | 311M | 230M | -123M | 238M | -46.0M | -99.0M | 83.0M | 304M | 635M |
| Net Income | 32.1M | 60.9M | 263M | 134M | -148M | 205M | -44.0M | -129M | 2.00M | 210M | 464M |
| EPS | 0.22 | 0.41 | 1.75 | 0.89 | -1.01 | 1.33 | -0.32 | -0.91 | 0.02 | 1.64 | 3.80 |
| Balance Sheet | |||||||||||
| Total Assets | 1.21B | 1.44B | 1.55B | 1.65B | 1.53B | 1.83B | 1.78B | 1.77B | 1.32B | 1.20B | 1.33B |
| Total Liabilities | 1.50B | 1.65B | 1.48B | 1.44B | 1.45B | 1.63B | 1.73B | 1.96B | 1.67B | 1.30B | 1.39B |
| Shareholders' Equity | -295M | -203M | 66.0M | 209M | 82.0M | 203M | 51.3M | -191M | -348M | -99.0M | -60.0M |
| Cash & Short-term Investments | 692M | 863M | 924M | 1.06B | 858M | 1.10B | 898M | 410M | 320M | 195M | 305M |
| Total Debt | 535M | 482M | 241M | 293M | 285M | 286M | 277M | 283M | 375M | 351M | 501M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 407M | 295M | 303M | 151M | -193M | 353M | -4.00M | -300M | 36.0M | -27.0M | 423M |
| Capital Expenditure | 35.0M | 43.0M | 41.0M | 7.00M | 4.00M | 34.0M | 5.00M | 53.0M | 31.0M | 67.0M | 54.7M |
| Free Cash Flow | 372M | 252M | 262M | 144M | -197M | 319M | -9.00M | -353M | 5.00M | -94.0M | 368M |
| Ratios | |||||||||||
| ROE | - | - | 398.0% | 64.1% | -180.5% | 101.0% | -85.8% | - | - | - | - |
| ROA | 2.7% | 4.2% | 17.0% | 8.1% | -9.7% | 11.2% | -2.5% | -7.3% | 0.2% | 17.5% | 34.8% |
| Net Profit Margin | 3.3% | 5.3% | 27.4% | 17.1% | -22.9% | 25.9% | -4.9% | -11.8% | 0.2% | 16.9% | 34.3% |
| Debt to Equity | - | - | 3.65x | 1.40x | 3.48x | 1.41x | 5.40x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Indivior PLC Ordinary Shares dividends
Indivior PLC Ordinary Shares has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Oct 11, 2022.
Who owns Indivior PLC Ordinary Shares
- Insiders 1.02%
- Institutions 59.66%
- Public & others 39.31%
- Shares outstanding 118M
- Free float 109M
Top funds holding INDV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7.10M | 5.68% | -0.08% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.75M | 3.00% | -3.43% | Sep 2026 |
| iShares Russell 2000 ETF | 3.04M | 2.43% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 2.66M | 2.13% | -5.27% | Sep 2026 |
| FullerThaler Behavioral Sm-Cp Gr R6 | 2.15M | 1.72% | +2.80% | Jun 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.48M | 1.18% | -8.25% | Sep 2026 |
| Fidelity Small Cap Index | 1.31M | 1.05% | +0.15% | Aug 2026 |
| FullerThaler Behavioral Sm-Cp Eq R6 | 1.23M | 0.99% | +4.25% | Jun 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 1.08M | 0.86% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 1.06M | 0.85% | -0.20% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 998K | 0.80% | -0.38% | Oct 2026 |
| Harbor Small Cap Growth Instl | 924K | 0.74% | +81.27% | Sep 2026 |
| Invesco S&P SmallCap Momentum ETF | 891K | 0.71% | 0.00% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 752K | 0.60% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 697K | 0.56% | +1.13% | Sep 2026 |
| Oberweis Small-Cap Opportunities | 688K | 0.55% | +18.74% | Jun 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 674K | 0.54% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 627K | 0.50% | +0.24% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 613K | 0.49% | 0.00% | Sep 2026 |
| Federated Hermes MDT Small Cap Core IS | 607K | 0.49% | +3.12% | Sep 2026 |
Top institutions holding INDV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 18.7M | 14.96% | +0.90% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 7.57M | 6.06% | -4.05% | Jun 2026 |
| Oaktree Capital Management LLC | 6.13M | 4.90% | -12.27% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.50M | 4.40% | -1.63% | Jun 2026 |
| State Street Corp | 4.99M | 3.99% | +1.80% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 4.62M | 3.69% | +1.90% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.40M | 2.72% | -3.14% | Jun 2026 |
| Franklin Templeton Inc | 3.32M | 2.65% | +2,871.83% | Jun 2026 |
| Geode Capital Management, LLC | 3.16M | 2.53% | +8.00% | Jun 2026 |
| Assenagon Asset Management SA | 3.08M | 2.47% | 0.00% | Jun 2026 |
| Madison Avenue Partners, LP | 2.87M | 2.30% | -33.39% | Jun 2026 |
| Mangrove Partners | 2.68M | 2.14% | -2.40% | Jun 2026 |
| Citadel Advisors Llc | 2.67M | 2.13% | -25.36% | Jun 2026 |
| Driehaus Capital Management LLC | 2.30M | 1.84% | +22.29% | Jun 2026 |
| Millennium Management LLC | 2.10M | 1.68% | -54.33% | Jun 2026 |
| Amvescap Plc. | 1.84M | 1.47% | +18.01% | Jun 2026 |
| Deerfield Management Co | 1.65M | 1.32% | -46.77% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.64M | 1.31% | -29.32% | Jun 2026 |
| Federated Hermes Inc | 1.47M | 1.17% | +20.61% | Jun 2026 |
| Newtyn Management LLC | 1.31M | 1.04% | -34.71% | Jun 2026 |
Indivior PLC Ordinary Shares company profile
- Company name
- Indivior PLC Ordinary Shares
- Ticker
- INDV.US
- Exchange
- USA Stocks
- Listed since
- Dec 29, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 827
- Fiscal year end
- December
- Address
- 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235
- Phone
- 804 379 1040
- Website
- indivior.com
About Indivior PLC Ordinary Shares
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior PLC Ordinary Shares management
10- Mr. Joseph J. CiaffoniCEO & Director · born 1971
- Mr. Ryan PreblickChief Financial Officer · born 1976
- Dr. Christian HeidbrederChief Scientific Officer · born 1963
- Mr. Jeffrey W. Burris J.D.Chief Legal Officer · born 1972
- Mr. Patrick a. BarryChief Commercial Officer · born 1968
- Mr. Jason ThompsonVice President of Investor Relations
- Mr. Kevin L. EspinozaChief Integrity & Compliance Officer
- Ms. Angela Colon-Mahoney M.S.Chief Human Resources Officer · born 1976
- Ms. Vanessa ProcterExecutive Vice President of Corporate Affairs
- Dr. Ann Wheeler Pharm.D.Chief Medical Officer